{"id":"W2948216318","doi":"10.1186/s12933-019-0864-7","title":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential","year":2019,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Wilfrid Laurier University; Canadian Heart Research Centre; University of Ottawa; Université Laval","funders":"Servier; Otsuka Pharmaceutical; Shionogi; Astellas Pharma; Ionis Pharmaceuticals; Mylan; Amarin Corporation; Daiichi Sankyo Europe; Kowa Company; Sanofi; Regeneron Pharmaceuticals; Daiichi-Sankyo; Teva Pharmaceutical Industries; AstraZeneca; Pfizer; Amgen","keywords":"Dyslipidemia; Medicine; Peroxisome proliferator-activated receptor alpha; Diabetes mellitus; Peroxisome proliferator-activated receptor; Internal medicine; Agonist; Type 2 Diabetes Mellitus; Type 2 diabetes; PPAR agonist; Bioinformatics; Endocrinology; Pharmacology; Receptor; Nuclear receptor; Biology; Biochemistry; Transcription factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008945457,0.001488658,0.003874148,0.0002055482,0.0006234658,0.0001919043,0.00109468,0.002910311,0.00003181059],"category_scores_gemma":[0.0004016912,0.001107621,0.002603541,0.0005795413,0.001286823,0.00001984886,0.0005428785,0.001729413,0.0001467961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002235422,"about_ca_system_score_gemma":0.0009668085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007473558,"about_ca_topic_score_gemma":0.000001041348,"domain_scores_codex":[0.9922476,0.002409346,0.001033499,0.002214386,0.0006062738,0.001488928],"domain_scores_gemma":[0.9961828,0.0002867882,0.0005605221,0.002287847,0.0002865123,0.0003955467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004397839,0.0003216347,0.0002921592,0.003978491,0.06990737,0.00004866354,0.0003051529,0.0001323649,0.01521099,0.001450392,0.002984489,0.9049285],"study_design_scores_gemma":[0.0008201624,0.0003759092,0.00001144618,0.0005568096,0.00251105,0.0002789293,0.00006853524,0.00001166862,0.008155748,0.0001363092,0.9857348,0.001338594],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01123265,0.9827744,0.0005755632,0.0000532817,0.002196096,0.002857946,0.0001493066,0.0001051742,0.00005552549],"genre_scores_gemma":[0.03007348,0.9660433,0.0001343414,0.0001560214,0.001543828,0.001067261,0.0005109471,0.0003588844,0.0001119489],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9827504,"threshold_uncertainty_score":0.9997863,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02160512217517304,"score_gpt":0.2743817738326816,"score_spread":0.2527766516575086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}